Causes of Mortality After Dose-Escalated Radiation Therapy and Androgen Deprivation for High-Risk Prostate Cancer

被引:16
|
作者
Tendulkar, Rahul D. [1 ]
Hunter, Grant K. [2 ]
Reddy, Chandana A. [1 ]
Stephans, Kevin L. [1 ]
Ciezki, Jay P. [1 ]
Abdel-Wahab, May [1 ]
Stephenson, Andrew J. [3 ]
Klein, Eric A. [3 ]
Mahadevan, Arul [4 ]
Kupelian, Patrick A. [5 ]
机构
[1] Cleveland Clin, Dept Radiat Oncol, Taussig Canc Inst, Cleveland, OH 44195 USA
[2] Intermt Healthcare, Dept Radiat Oncol, Salt Lake City, UT USA
[3] Cleveland Clin, Dept Urol, Glickman Urol Inst, Cleveland, OH 44195 USA
[4] Seacoast Canc Ctr New Hampshire, Dover, NH USA
[5] Univ Calif Los Angeles Hlth Syst, Los Angeles, CA USA
关键词
RANDOMIZED CONTROLLED-TRIAL; RADIOTHERAPY; SUPPRESSION;
D O I
10.1016/j.ijrobp.2013.05.044
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Men with high-risk prostate cancer have other competing causes of mortality; however, current risk stratification schema do not account for comorbidities. We aim to identify the causes of death and factors predictive for mortality in this population. Methods and Materials: A total of 660 patients with high-risk prostate cancer were treated with definitive high-dose external beam radiation therapy (>= 74 Gy) and androgen deprivation (AD) between 1996 and 2009 at a single institution. Cox proportional hazards regression analysis was conducted to determine factors predictive of survival. Results: The median radiation dose was 78 Gy, median duration of AD was 6 months, and median follow-up was 74 months. The 10-year overall survival (OS) was 60.6%. Prostate cancer was the leading single cause of death, with 10-year mortality of 14.1% (95% CI 10.7-17.6), compared with other cancers (8.4%, 95% CI 5.7-11.1), cardiovascular disease (7.3%, 95% CI 4.7-9.9), and all other causes (10.4%, 95% CI 7.2-13.6). On multivariate analysis, older age (HR 1.55, P=.002) and Charlson comorbidity index score (CS) >= 1 (HR 2.20, P<.0001) were significant factors predictive of OS, whereas Gleason score, T stage, prostate-specific antigen, duration of AD, radiation dose, smoking history, and body mass index were not. Men younger than 70 years of age with CS = 0 were more likely to die of prostate cancer than any other cause, whereas older men or those with CS >= 1 more commonly suffered non-prostate cancer death. The cumulative incidences of prostate cancer-specific mortality were similar regardless of age or comorbidities (P=.60). Conclusions: Men with high-risk prostate cancer are more likely to die of causes other than prostate cancer, except for the subgroup of men younger than 70 years of age without comorbidities. Only older age and presence of comorbidities significantly predicted for OS, whereas prostate cancer- and treatment-related factors did not. (C) 2013 Elsevier Inc.
引用
收藏
页码:94 / 99
页数:6
相关论文
共 50 条
  • [21] Androgen Deprivation Therapy in High-Risk Prostate Cancer
    Buyyounouski, Mark K.
    [J]. ONCOLOGY-NEW YORK, 2010, 24 (09): : 806 - 809
  • [22] The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-Risk Prostate Cancer
    Bian, S.
    Kuban, D. A.
    Levy, L. B.
    Oh, J.
    Choi, S.
    McGuire, S. E.
    Pugh, T. J.
    Nguyen, P. L.
    Lee, A. K.
    Hoffman, K. E.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S370 - S371
  • [23] The Current Role of Androgen Deprivation in Patients Undergoing Dose-Escalated External Beam Radiation Therapy for Clinically Localized Prostate Cancer
    Smith, Michael J.
    Akhtar, Naveed H.
    Tagawa, Scott T.
    [J]. PROSTATE CANCER, 2012, 2012
  • [24] The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer
    Bian, Shelly X.
    Kuban, Deborah A.
    Levy, Lawrence B.
    Oh, Jeong
    Choi, Seungtaek
    McGuire, Sean E.
    Frank, Steven J.
    Mahmood, Usama
    Nguyen, Paul L.
    Pugh, Thomas J.
    Lee, Andrew K.
    Hoffman, Karen E.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (04): : 368 - 373
  • [25] Incorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer
    Dosoretz, Arie P.
    Yu, James B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1718 - +
  • [26] Short-term Androgen-Deprivation Therapy Improves Prostate Cancer-Specific Mortality in Intermediate-Risk Prostate Cancer Patients Undergoing Dose-Escalated External Beam Radiation Therapy
    Zumsteg, Zachary S.
    Spratt, Daniel E.
    Pei, Xin
    Yamada, Yoshiya
    Kalikstein, Abraham
    Kuk, Deborah
    Zhang, Zhigang
    Zelefsky, Michael J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 85 (04): : 1012 - 1017
  • [27] Androgen Deprivation Therapy and Dose- Escalated Radiotherapy for Intermediate- and High-Risk Prostate Cancer: Sign of Changing Times?
    Dalela, Deepansh
    Karabon, Patrick
    Abdollah, Firas
    [J]. JAMA ONCOLOGY, 2017, 3 (02) : 280 - 281
  • [28] REDEFINING HIGH-RISK PROSTATE CANCER BASED ON DISTANT METASTASES AND MORTALITY AFTER HIGH-DOSE RADIOTHERAPY WITH ANDROGEN DEPRIVATION THERAPY
    Tendulkar, Rahul D.
    Reddy, Chandana A.
    Stephans, Kevin L.
    Ciezki, Jay P.
    Klein, Eric A.
    Mahadevan, Arul
    Kupelian, Patrick A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (04): : 1397 - 1404
  • [29] Variations in Patterns of Concurrent Androgen Deprivation Therapy (ADT) Use Based on Standard Dose Versus Dose-Escalated Radiation Therapy (DE RT) for Prostate Cancer
    Mohiuddin, J. J.
    Narayan, V.
    Venigalla, S.
    Vapiwala, N.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E130 - E130
  • [30] Hypofractionated radiation therapy combined with androgen deprivation therapy for high-risk localized prostate cancer
    Lee, Tae Hoon
    Pyo, Hongryull
    Yoo, Gyu Sang
    Jeon, Seong Soo
    Seo, Seong Il
    Jeong, Byong Chang
    Jeon, Hwang Gyun
    Sung, Hyun Hwan
    Kang, Minyong
    Song, Wan
    Chung, Jae Hoon
    Bae, Bong Kyung
    Park, Won
    [J]. JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2024, 68 (03) : 333 - 341